United Therapeutics Wins Appeal In Dry Powder Inhaler Patent Litigation
Portfolio Pulse from Happy Mohamed
United Therapeutics Corporation (UTHR) has won an appeal in a patent litigation case against Liquidia Technologies, Inc. The United States Court of Appeals for the Federal Circuit affirmed that Liquidia's proposed Yutrepia™ product infringes a United Therapeutics' patent, preventing the FDA from granting Liquidia final approval for its Yutrepia product until the patent expires in 2027. The court also affirmed that certain claims of another United Therapeutics patent are either invalid or not infringed by Liquidia.
July 24, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics' win in the patent litigation case against Liquidia Technologies could potentially strengthen its market position by blocking a competitor's product until 2027.
The court's decision prevents Liquidia from receiving FDA approval for its Yutrepia product until 2027, reducing competition for United Therapeutics. This could potentially lead to increased market share and revenues for United Therapeutics, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100